Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | PDE6D | O43924 | 1/20 | 0.33 |
| ▸ | PDE6A | P16499 | 1/20 | 0.33 |
| ▸ | PDE6G | P18545 | 1/20 | 0.33 |
| ▸ | PDE6B | P35913 | 1/20 | 0.33 |
| ▸ | PDE6C | P51160 | 1/20 | 0.33 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535685 | 0.90 | MCHR1 (0.34) | — | |
| SCHEMBL22121629 | 0.81 | GBA1 (0.42) | — | |
| SCHEMBL1559517 | 0.69 | DAO (0.33) | — | |
| SCHEMBL27153733 | 0.64 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL20536176 | 0.63 | PRMT5 (0.33) | — | |
| SCHEMBL26120649 | 0.61 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL23910454 | 0.61 | MAPK1 (0.35) | MAPK1CYP3A4CYP2C9CYP2C19HTR6 | |
| SCHEMBL18367452 | 0.61 | CNR1 (0.41) | MAPK1CYP3A4CYP2C9CYP2C19HTR6 | |
| SCHEMBL1693802 | 0.61 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL9957570 | 0.60 | BRS3 (0.39) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | claimed |